Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes

Bibliography

• DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773–95
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2015;58:429–42
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Paquot N. Metformin revisited: A critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab 2013;39:179–90
   PubMed Web of Science ®Google Scholar
• Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013;15:938–53
   PubMed Web of Science ®Google Scholar
• Zhang Y, Hong J, Chi J, et al. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials. Diabetes Metab Res Rev 2014;30:241–56
   PubMed Web of Science ®Google Scholar
• Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009;339:b4731
   PubMed Web of Science ®Google Scholar
• Gillies PS, Dunn CJ. Pioglitazone. Drugs 2000;60:333–43
   PubMed Web of Science ®Google Scholar
• Waugh J, Keating GM, Plosker GL, et al. Pioglitazone: a review of its use in type 2 diabetes mellitus. Drugs 2006;66:85–109
   PubMed Web of Science ®Google Scholar
• Scheen AJ. A review of gliptins in 2011. Expert Opin Pharmacother 2012;13:81–99
   PubMed Web of Science ®Google Scholar
• Scheen AJ. A review of gliptins for 2014. Exp Opin Pharmacother 2015;16:43–62
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106–18
   PubMed Web of Science ®Google Scholar
• Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 2003;63:1373–405
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279–89
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Tan MH, Betteridge DJ, et al. Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18). Diabet Med 2009;26:1242–9
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Tan MH, Betteridge DJ, et al. Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17). Diabet Med 2009;26:1033–9
   PubMed Web of Science ®Google Scholar
• Charbonnel B, DeFronzo R, Davidson J, et al. Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19). J Clin Endocrinol Metab 2010;95:2163–71
   PubMed Web of Science ®Google Scholar
• Scott LJ. Alogliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2010;70:2051–72
   PubMed Web of Science ®Google Scholar
• Seino Y, Yabe D. Alogliptin benzoate for the treatment of type 2 diabetes. Expert Opin Pharmacother 2014;15:851–63
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opin Drug Saf 2015;14:505–24
   PubMed Web of Science ®Google Scholar
• Triplitt C, Cersosimo E, DeFronzo RA. Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment. Vasc Health Risk Manag 2010;6:671–90
   PubMedGoogle Scholar
• Argyrakopoulou G, Doupis J. DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy. Adv Ther 2009;26:272–80
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Inzucchi SE, Seufert J, et al. Initial combination therapy with alogliptin and pioglitazone in drug-naive patients with type 2 diabetes. Diabetes Care 2010;33:2406–8
   PubMed Web of Science ®Google Scholar
• Henry RR, Staels B, Fonseca VA, et al. Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone-a factorial study. Diabetes Obes Metab 2014;16:223–30
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Incresync: summary of product characteristics. 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002178/WC500152197.pdf [Last accessed 16 March 2015]
   Google Scholar
• Eckland DA, Danhof M. Clinical pharmacokinetics of pioglitazone. Exp Clin Endocrinol Diabetes 2000;108:234–42
   Web of Science ®Google Scholar
• Hanefeld M. Pharmacokinetics and clinical efficacy of pioglitazone. Int J Clin Pract Suppl 2001;121:19–25
   PubMedGoogle Scholar
• Wittayalertpanya S, Chompootaweep S, Thaworn N. The pharmacokinetics of pioglitazone in Thai healthy subjects. J Med Assoc Thai 2006;89:2116–22
   PubMedGoogle Scholar
• European Medicines Agency. Pioglitazone (Actos). European public assessment report: scientific discussion. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000285/WC500021381.pdf 2003. [Last accessed 16 March 2015]
   Google Scholar
• Fritsche L, Budde K, Glander P, et al. Treating type 2 diabetes in renal insufficiency: the role of pioglitazone. Int J Clin Pharmacol Ther 2003;41:488–91
   PubMed Web of Science ®Google Scholar
• Budde K, Neumayer HH, Fritsche L, et al. The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol 2003;55:368–74
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease. Expert Opin Drug Metab Toxicol 2014;10:839–57
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetic interactions with thiazolidinediones. Clin Pharmacokinet 2007;46:1–12
   PubMed Web of Science ®Google Scholar
• Tornio A, Niemi M, Neuvonen PJ, et al. Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metab Dispos 2008;36:73–80
   PubMed Web of Science ®Google Scholar
• Jaakkola T, Laitila J, Neuvonen PJ, et al. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol 2006;99:44–51
   PubMed Web of Science ®Google Scholar
• Jaakkola T, Backman JT, Neuvonen M, et al. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther 2005;77:404–14
   PubMed Web of Science ®Google Scholar
• Tornio A, Filppula AM, Kailari O, et al. Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions. Clin Pharmacol Ther 2014;96:498–507
   PubMed Web of Science ®Google Scholar
• Kadam R, Bourne D, Kompella U, et al. Effect of cytochrome P450 2C8*3 on the population pharmacokinetics of pioglitazone in healthy Caucasian volunteers. Biol Pharm Bull 2013;36:245–51
   PubMed Web of Science ®Google Scholar
• Aquilante CL, Kosmiski LA, Bourne DW, et al. Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone. Br J Clin Pharmacol 2013;75:217–26
   PubMed Web of Science ®Google Scholar
• Aquilante CL, Wempe MF, Spencer SH, et al. Influence of CYP2C8*2 on the pharmacokinetics of pioglitazone in healthy African-American volunteers. Pharmacotherapy 2013;33:1000–7
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010;12:648–58
   PubMed Web of Science ®Google Scholar
• Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet 2012;51:501–14
   PubMed Web of Science ®Google Scholar
• Christopher R, Covington P, Davenport M, et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther 2008;30:513–27
   PubMed Web of Science ®Google Scholar
• Karim A, Laurent A, Munsaka M, et al. Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants. J Clin Pharmacol 2009;49:1210–19
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Vipidia (alogliptin). Committee for Medicinal Products for Human Use (CHMP) Assessment Report. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002182/WC500152273.pdf [Last accessed on 16 March 2015]
   Google Scholar
• Karim A, Covington P, Christopher R, et al. Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects. Int J Clin Pharmacol Ther 2010;48:46–58
   PubMed Web of Science ®Google Scholar
• Covington P, Christopher R, Davenport M, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther 2008;30:499–512
   PubMed Web of Science ®Google Scholar
• Karim A, Fleck P, Hetman L, et al. Single-dose pharmacokinetics of the dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment. Diabetes 2008;57(Suppl 1):A160
   Google Scholar
• Karim A, Fleck P, Dorsey D, et al. Single dose pharmacokinetics of alogliptin benzoate(SYR-322) in subjects with moderate hepatic impairment. J Clin Pharmacol 2007;47:1207
   Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus. Clin Pharmacokinet 2014;53:773–85
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet 2010;49:573–88
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Burant CF, Fleck P, et al. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. J Clin Endocrinol Metab 2012;97:1615–22
   PubMed Web of Science ®Google Scholar
• Pratley RE, Reusch JE, Fleck PR, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 2009;25:2361–71
   PubMed Web of Science ®Google Scholar
• Bosi E, Ellis GC, Wilson CA, et al. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes Obes Metab 2011;13:1088–96
   PubMed Web of Science ®Google Scholar
• Kaku K, Itayasu T, Hiroi S, et al. Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study. Diabetes Obes Metab 2011;13:1028–35
   PubMed Web of Science ®Google Scholar
• Tanaka T, Nangaku M, Nishiyama A. The role of incretins in salt-sensitive hypertension: the potential use of dipeptidyl peptidase-IV inhibitors. Curr Opin Nephrol Hypertens 2011;20:476–81
   PubMed Web of Science ®Google Scholar
• Masuda T, Fu Y, Eguchi A, et al. Dipeptidyl peptidase IV inhibitor lowers PPARgamma agonist-induced body weight gain by affecting food intake, fat mass, and beige/brown fat but not fluid retention. Am J Physiol Endocrinol Metab 2014;306:E388–98
   PubMed Web of Science ®Google Scholar
• Moritoh Y, Takeuchi K, Asakawa T, et al. The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. Eur J Pharmacol 2009;602:448–54
   PubMed Web of Science ®Google Scholar
• Moritoh Y, Takeuchi K, Asakawa T, et al. Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice. Br J Pharmacol 2009;157:415–26
   PubMed Web of Science ®Google Scholar
• Yin H, Park SY, Wang XJ, et al. Enhancing pancreatic Beta-cell regeneration in vivo with pioglitazone and alogliptin. PLoS One 2013;8:e65777
   PubMedGoogle Scholar
• Eliasson B, Moller-Goede D, Eeg-Olofsson K, et al. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia 2012;55:915–25
   PubMed Web of Science ®Google Scholar
• Van Raalte DH, van Genugten RE, Eliasson B, et al. The effect of alogliptin and pioglitazone combination therapy on various aspects of beta-cell function in patients with recent-onset type 2 diabetes. Eur J Endocrinol 2014;170:565–74
   PubMed Web of Science ®Google Scholar
• Turner RM, Kwok CS, Chen-Turner C, et al. Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis. Br J Clin Pharmacol 2014;78:258–73
   PubMed Web of Science ®Google Scholar
• Kostapanos MS, Elisaf MS, Mikhailidis DP. Pioglitazone and cancer: angel or demon? Curr Pharm Des 2013;19:4913–29
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. European Medicines Agency clarifies opinion on pioglitazone and the risk of bladder cancer. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/10/news_detail_001368.jsp&mid=WC0b01ac058004d5c1 2011. [Last accessed on 16 March 2015]
   Google Scholar
• Shah P, Mudaliar S. Pioglitazone: side effect and safety profile. Expert Opin Drug Saf 2010;9:347–54
   PubMed Web of Science ®Google Scholar
• Barbehenn E, Almashat S, Carome M, et al. Hepatotoxicity of alogliptin. Clin Pharmacokinet 2014;53:1055–6
   PubMed Web of Science ®Google Scholar
• Scheen A. Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis. Expert Opin Drug Saf 2013;12:545–57
   PubMed Web of Science ®Google Scholar
• Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs-FDA and EMA assessment. N Engl J Med 2014;370:794–7
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Oseni (alogliptin-pioglitazone). Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022426s000lbl.pdf 2013. [Last accessed 16 March 2015]
   Google Scholar
• Scheen AJ. Hepatotoxicity with thiazolidinediones: is it a class effect? Drug Saf 2001;24:873–88
   PubMedGoogle Scholar
• Yki-Jarvinen H. Thiazolidinediones and the liver in humans. Curr Opin Lipidol 2009;20:477–83
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Alogliptin risk management review. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000RiskR.pdf 2013. [Last accessed on 16 March 2015]
   Google Scholar
• Scheen AJ. Alogliptin: concern about hepatotoxicity? Clin Pharmacokinet 2014;53:1057–9
   PubMed Web of Science ®Google Scholar
• Xu P, Xu K, Wang J, et al. Pioglitazone: a promising therapeutic tool in sodium taurocholate-induced severe acute pancreatitis. Dig Dis Sci 2011;56:1082–9
   PubMed Web of Science ®Google Scholar
• Li L, Shen J, Bala MM, et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ 2014;348:g2366
   PubMed Web of Science ®Google Scholar
• Goldfine AB. Assessing the cardiovascular safety of diabetes therapies. N Engl J Med 2008;359:1092–5
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457–71
   PubMed Web of Science ®Google Scholar
• Schernthaner G. Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors. Int J Clin Pract 2009;63:912–29
   PubMed Web of Science ®Google Scholar
• Tannen R, Xie D, Wang X, et al. A new “Comparative Effectiveness” assessment strategy using the THIN database: comparison of the cardiac complications of pioglitazone and rosiglitazone. Pharmacoepidemiol Drug Saf 2013;22:86–97
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Outcomes and lessons from the PROactive study. Diabetes Res Clin Pract 2012;98:175–86
   PubMed Web of Science ®Google Scholar
• White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327–35
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317–26
   PubMed Web of Science ®Google Scholar
• Karalliedde J, Buckingham RE. Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies. Drug Saf 2007;30:741–53
   PubMed Web of Science ®Google Scholar
• Erdmann E, Charbonnel B, Wilcox RG, et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 2007;30:2773–8
   PubMed Web of Science ®Google Scholar
• Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007;370:1129–36
   PubMed Web of Science ®Google Scholar
• Mannucci E, Monami M, Lamanna C, et al. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes Metab 2008;10:1221–38
   PubMed Web of Science ®Google Scholar
• Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012;33:187–215
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Cardiovascular effects of gliptins. Nat Rev Cardiol 2013;10:73–84
   PubMed Web of Science ®Google Scholar
• Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin and diabetes mellitus: observations from the SAVOR - TIMI 53 randomized trial. Circulation 2014;130:1579–88
   PubMed Web of Science ®Google Scholar
• Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2014;24:689–97
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Day C. Fixed-dose single tablet antidiabetic combinations. Diabetes Obes Metab 2009;11:527–33
   PubMed Web of Science ®Google Scholar
• Han S, Iglay K, Davies MJ, et al. Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: a meta-analysis. Curr Med Res Opin 2012;28:969–77
   PubMed Web of Science ®Google Scholar
• Bell DS. Combine and conquer: advantages and disadvantages of fixed-dose combination therapy. Diabetes Obes Metab 2013;15:291–300
   PubMed Web of Science ®Google Scholar
• Williams SA, Buysman EK, Hulbert EM, et al. Hemoglobin A1c outcomes and health care resource use in type 2 diabetes mellitus patients treated with combination oral antidiabetic drugs through step therapy and loose-dose and fixed-dose combinations. Manag Care 2012;21:40–8
   PubMedGoogle Scholar
• Benford M, Milligan G, Pike J, et al. Fixed-dose combination antidiabetic therapy: real-world factors associated with prescribing choices and relationship with patient satisfaction and compliance. Adv Ther 2012;29:26–40
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin. Expert Opin Drug Metab Toxicol 2010;6:1265–76
   PubMed Web of Science ®Google Scholar
• Guarino E, Nigi L, Patti A, et al. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus. Expert Opin Pharmacother 2012;13:1377–84
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Metformin + saxagliptin for type 2 diabetes. Expert Opin Pharmacother 2012;13:139–46
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Linagliptin plus metformin : a pharmacokinetic and pharmacodynamic evaluation. Expert Opin Drug Metab Toxicol 2013;9:363–77
   PubMed Web of Science ®Google Scholar
• Pratley RE, Fleck P, Wilson C. Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naive patients with type 2 diabetes: a randomized, double-blind, 6-month study. Diabetes Obes Metab 2014;16:613–21
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol 2012;8:745–58
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 2015;75:33–59
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care 2015;38:376–83
   PubMed Web of Science ®Google Scholar
• Friedrich C, Metzmann K, Rose P, et al. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers. Clin Ther 2013;35:A33–42
   PubMed Web of Science ®Google Scholar
• Scheen AJ. SGLT2 versus DPP4 inhibitors for type 2 diabetes. Lancet Diabetes Endocrinol 2013;1:168–70
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Green BD, Flatt PR. Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone. Expert Opin Investig Drugs 2010;19:1017–25
   PubMed Web of Science ®Google Scholar
• Yoon KH, Shockey GR, Teng R, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of beta-cell function in patients with type 2 diabetes. Int J Clin Pract 2011;65:154–64
   PubMed Web of Science ®Google Scholar
• Yoon KH, Steinberg H, Teng R, et al. Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study. Diabetes Obes Metab 2012;14:745–52
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Radermecker RP. Addition of incretin therapy to metformin in type 2 diabetes. Lancet 2010;375:1410–12
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Paquot N. Gliptin versus a sulphonylurea as add-on to metformin. Lancet 2012;380:450–2
   PubMed Web of Science ®Google Scholar
• Holland DQ, Neumiller JJ. Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus. Diabetes Metab Syndr Obes 2014;7:277–88
   PubMedGoogle Scholar
• Cefalu WT, Buse JB, Del Prato S, et al. Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors’ expert forum. Diabetes Care 2014;37:2647–59
   PubMed Web of Science ®Google Scholar